Quest Diagnostics (DGX) vs Henry Schein (HSIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Henry Schein (HSIC) has outperformed Quest Diagnostics (DGX) over the past year, gaining 30.7% versus a gain of 27.6%. Over five years, DGX leads with a +62.0% price change compared with +9.3% for HSIC. Quest Diagnostics is the larger company by market cap ($25.49 billion vs $9.36 billion), about 2.7 times the size.
On valuation, Henry Schein trades at a lower forward P/E (14.0x vs 19.2x for Quest Diagnostics). Quest Diagnostics pays a dividend yielding 1.44%, while Henry Schein does not currently pay one. Quest Diagnostics converts more of its revenue into profit, with a net margin of 9.0% versus 3.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DGX | HSIC |
|---|---|---|
| Share price | $230.97 | $84.01 |
| Market cap | $25.49B | $9.36B |
| 1-day change | +0.07% | -0.73% |
| YTD return | +33.01% | +11.97% |
| 1-year return | +27.60% | +30.74% |
| 5-year return | +61.97% | +9.28% |
| P/E ratio (TTM) | 24.52 | 24.49 |
| Forward P/E | 19.19 | 14.04 |
| EPS (TTM) | $9.42 | $3.43 |
| Dividend yield | 1.44% | 0.00% |
| Annual dividend | $3.32 | $0.00 |
| Revenue (latest FY) | $11.04B | $13.18B |
| Revenue growth (YoY) | +11.78% | +4.03% |
| Net income (latest FY) | $992.00M | $398.00M |
| Gross margin | 33.21% | 31.14% |
| Operating margin | 14.10% | 4.95% |
| Net margin | 8.99% | 3.02% |
| 52-week high | $248.84 | $92.18 |
| 52-week low | $171.18 | $61.95 |
| Distance from 52-week high | -7.18% | -8.86% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +7.40% | +15.78% |
| Average volume | 1.04M | 1.22M |
| Shares outstanding | 110.37M | 111.45M |
| Employees | 46,000 | 25,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Quest Diagnostics is about 2.7 times larger than Henry Schein by market value ($25.49B vs $9.36B).
- Quest Diagnostics offers a meaningfully higher dividend yield (1.44% vs 0.00%).
- Quest Diagnostics is more profitable, keeping 9.0 cents of every revenue dollar as net income versus 3.0 cents for Henry Schein.
- Quest Diagnostics grew revenue faster in its latest fiscal year (+11.78% vs +4.03%).
About Quest Diagnostics
DGX stock →Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Health Care · Medical Specialities · 46,000 employees
About Henry Schein
HSIC stock →Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.
Health Care · Medical Specialities · 25,000 employees
DGX vs HSIC FAQ
Which is bigger, Quest Diagnostics or Henry Schein?
Quest Diagnostics (DGX) is larger, with a market capitalization of $25.49B compared with $9.36B for Henry Schein (HSIC).
Which stock has performed better over the past year, DGX or HSIC?
HSIC returned +30.74% over the past 12 months, compared with +27.60% for DGX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DGX or HSIC?
HSIC has the lower trailing P/E at 24.5, versus 24.5 for DGX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Quest Diagnostics or Henry Schein?
Quest Diagnostics pays a dividend yielding 1.44%, while Henry Schein does not currently pay a regular dividend.
Are Quest Diagnostics and Henry Schein in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.